AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19805698 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 600
Study 17173213 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate washes and 2% mupirocin ointment intranasally, with oral rifampin and doxycycline for 7 days
Number of subjects: 146
Study 17173213 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 146
Study 17173213 — intervention group
Group type: EXPERIMENTAL
Intervention: Decolonization therapy
Number of subjects: 146
Study 17173213 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin-resistant isolate at baseline
Number of subjects: 146
Study 14998805 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11486310 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) supported with autologous stem cells
Number of subjects: 0
Study 11486310 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan 200 mg/m(2)
Number of subjects: 0
Study 11486310 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpurged peripheral blood stem cells (PBSC)
Number of subjects: 0
Study 11486310 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem transplants
Number of subjects: 0
Study 9706915 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg x kg(‐1) x h(‐1))
Number of subjects: 36
Study 9706915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.25 microg x kg(‐1) x h(‐1) with bolus midazolam 2 mg)
Number of subjects: 36
Study 9706915 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.07‐0.15 microg x kg(‐1) x h(‐1))
Number of subjects: 36
Study 9706915 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 36
Study 8311209 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 40
Study 8311209 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 40
Study 30843421 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for 16 weeks
Number of subjects: 54
Study 30843421 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture for 16 weeks
Number of subjects: 54
Study 28193574 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm SGA
Number of subjects: 2510
Study 28193574 — intervention group
Group type: COMPARATOR
Intervention: Term AGA
Number of subjects: 2510
Study 28193574 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm AGA
Number of subjects: 2510
Study 28193574 — intervention group
Group type: EXPERIMENTAL
Intervention: Term SGA
Number of subjects: 2510
Study 26437606 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst stage transfer (BS group, n = 57)
Number of subjects: 118
Study 26437606 — intervention group
Group type: COMPARATOR
Intervention: Cleavage stage transfer (CS group, n = 61)
Number of subjects: 118
Study 26437606 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst stage transfer (BS group)
Number of subjects: 118
Study 26437606 — intervention group
Group type: COMPARATOR
Intervention: Cleavage stage transfer (CS group)
Number of subjects: 118
Study 22957771 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens-based pinhole
Number of subjects: 22
Study 22957771 — intervention group
Group type: COMPARATOR
Intervention: PureVision Multifocal contact lenses
Number of subjects: 22
Study 21950196 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg/day) for 12 weeks
Number of subjects: 13
Study 21950196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 21950196 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg/day)
Number of subjects: 13
Study 18490892 — intervention group
Group type: EXPERIMENTAL
Intervention: Early onset rehabilitation program (15 sessions of individual rehabilitation)
Number of subjects: 57
Study 18490892 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program (self-performed exercises after drain removal)
Number of subjects: 57
Study 16521172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sump-type tube on continuous suction drainage
Number of subjects: 34
Study 16521172 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lumen tube with free drainage and 4-hourly aspiration
Number of subjects: 34
Study 16521172 — intervention group
Group type: COMPARATOR
Intervention: No NG tube
Number of subjects: 34
Study 12664121 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 100
Study 12664121 — intervention group
Group type: COMPARATOR
Intervention: Iopromide
Number of subjects: 100
Study 10630440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution plus Lactobacillus GG (at least 10(10) CFU/250 ml)
Number of subjects: 287
Study 10630440 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution plus placebo
Number of subjects: 287
Study 8704460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-admission education programme
Number of subjects: 40
Study 8704460 — intervention group
Group type: COMPARATOR
Intervention: Information from ward staff on admission
Number of subjects: 40
Study 1531487 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 256
Study 1531487 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 256
Study 1531487 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment by general practitioner (GP)
Number of subjects: 256
Study 1531487 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (detuned ultrasound and detuned short wave diathermy)
Number of subjects: 256
Study 1531487 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 256
Study 3079991 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen‐permeable polyurethane dressing
Number of subjects: 0
Study 3079991 — intervention group
Group type: COMPARATOR
Intervention: Oxygen‐nonpermeable hydrocolloid dressing
Number of subjects: 0
Study 29691617 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for Achilles tendon rupture
Number of subjects: 100
Study 29691617 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment for Achilles tendon rupture
Number of subjects: 100
Study 27879147 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel agent induction regimens (including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs)) prior to HDM/SCT
Number of subjects: 45
Study 27879147 — intervention group
Group type: COMPARATOR
Intervention: No novel agent induction regimens prior to HDM/SCT
Number of subjects: 45
Study 27879147 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel agent induction regimens (including PIs and IMiDs) prior to HDM/SCT
Number of subjects: 45
Study 24939677 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab ≤3 mg/kg
Number of subjects: 462
Study 24939677 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3-5 mg/kg
Number of subjects: 462
Study 24939677 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab ≥5 mg/kg
Number of subjects: 462
Study 24939677 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (all doses)
Number of subjects: 462
Study 23126252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (600 mg daily)
Number of subjects: 15871
Study 23126252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15871
Study 23126252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Number of subjects: 15871
Study 20483049 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg) administered at week 0, 2, 6, and 14 along with stable dose of methotrexate
Number of subjects: 20
Study 20483049 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 18283230 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the quadriceps (15 patients)
Number of subjects: 26
Study 18283230 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy alone (11 patients)
Number of subjects: 26
Study 15768049 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF val66met genotype (val/val homozygotes, N=27)
Number of subjects: 44
Study 15768049 — intervention group
Group type: COMPARATOR
Intervention: BDNF val66met genotype
Number of subjects: 44
Study 12466380 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (1 mg/kg sc)
Number of subjects: 16
Study 12466380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10513498 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse-assisted coping skills training (CST)
Number of subjects: 88
Study 10513498 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional CST (no spouse involvement)
Number of subjects: 88
Study 10513498 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse-assisted CST
Number of subjects: 88
Study 10513498 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse-assisted CST and Conventional CST
Number of subjects: 88
Study 10513498 — intervention group
Group type: COMPARATOR
Intervention: Conventional CST and AE-SS control
Number of subjects: 88
Study 7796154 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg administered at 07.10 h
Number of subjects: 9
Study 7796154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7796154 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 9
Study 1710673 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance
Number of subjects: 42
Study 6115732 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg propranolol
Number of subjects: 6
Study 6115732 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg propranolol
Number of subjects: 6
Study 6115732 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sotalol
Number of subjects: 6
Study 6115732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31403867 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab (1 or 3 mg/kg via intravenous infusion every 2 weeks) + Axitinib (5 mg orally twice a day)
Number of subjects: 33
Study 31403867 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab + Axitinib
Number of subjects: 33
Study 28602137 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (Group 1 - 2.62 J)
Number of subjects: 60
Study 28602137 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (Group 2 - 5.24 J)
Number of subjects: 60
Study 28602137 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (Group 3 - 7.86 J)
Number of subjects: 60
Study 28602137 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study 27768192 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote care group using new tools for 6 months: remote and self-monitoring, self-adjustment of device, and a personalized online support tool
Number of subjects: 60
Study 27768192 — intervention group
Group type: COMPARATOR
Intervention: Control group following the standard care pathway
Number of subjects: 60
Study 24718019 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated communication training course
Number of subjects: 0
Study 24718019 — intervention group
Group type: COMPARATOR
Intervention: Case-based communication training course
Number of subjects: 0
Study 24718019 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 22912552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (DSM 9843)
Number of subjects: 214
Study 22912552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 19918967 — intervention group
Group type: EXPERIMENTAL
Intervention: Apilimod mesylate 50 mg daily
Number of subjects: 220
Study 19918967 — intervention group
Group type: EXPERIMENTAL
Intervention: Apilimod mesylate 100 mg daily
Number of subjects: 220
Study 19918967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 18853350 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater positive partner support to quit smoking
Number of subjects: 333
Study 18853350 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority status
Number of subjects: 333
Study 15647885 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective intravaginal electrical stimulation (IES)
Number of subjects: 40
Study 15647885 — intervention group
Group type: COMPARATOR
Intervention: Sham intravaginal electrical stimulation (IES)
Number of subjects: 40
Study 15647885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 40
Study 12824968 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate colposcopy
Number of subjects: 1572
Study 12824968 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV triage
Number of subjects: 1572
Study 12824968 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management (repeat cytology at HSIL threshold)
Number of subjects: 1572
Study 12824968 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cytology thresholds
Number of subjects: 1572
Study 10397121 — intervention group
Group type: EXPERIMENTAL
Intervention: IV glucagon (1 mg)
Number of subjects: 60
Study 10397121 — intervention group
Group type: COMPARATOR
Intervention: Nonglucagon (control)
Number of subjects: 60
Study 8893686 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid from women with moderate or severe endometriosis
Number of subjects: 30
Study 8893686 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal fluid from women with fertile women without endometriosis
Number of subjects: 30
Study 8893686 — intervention group
Group type: EXPERIMENTAL
Intervention: Percoll‐purified sperm fractions with peritoneal fluid from women with moderate or severe endometriosis
Number of subjects: 30
Study 1725004 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 21
Study 1725004 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 21
Study 6151789 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency transcutaneous nerve stimulation (TNS) at 2 Hz for 30-45 min
Number of subjects: 21
Study 30482055 — intervention group
Group type: EXPERIMENTAL
Intervention: KiSS treatment (multicomponent six-session program including CBT-I, hypnotherapy, and imaginations)
Number of subjects: 45
Study 30482055 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 45
Study 31178421 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled 7% hypertonic saline nebulised twice daily for 48 weeks
Number of subjects: 150
Study 31178421 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic saline nebulised twice daily for 48 weeks
Number of subjects: 150
Study 29328838 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 3mg/kg intravenously over 20 minutes prior to skin incision
Number of subjects: 36
Study 29328838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 400mg orally twice daily, commencing three days prior to surgery
Number of subjects: 36
Study 29328838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 36
Study 25357187 — intervention group
Group type: EXPERIMENTAL
Intervention: Thread-traction method (TT method)
Number of subjects: 40
Study 25357187 — intervention group
Group type: COMPARATOR
Intervention: Conventional ESD (group C)
Number of subjects: 40
Study 24005882 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) (808 nm; 100 mW; 35.7 W/cm(2), 357.14 J/cm(2) per point, energy of 1 J per point applied for 10 s on four points of the biceps brachii belly of each arm)
Number of subjects: 22
Study 24005882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 24005882 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 22
Study 23007025 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible PD solution (Balance®, Fresenius; LS)
Number of subjects: 63
Study 23007025 — intervention group
Group type: COMPARATOR
Intervention: Conventional PD solution (CAPD/DPCA®, Fresenius; CS)
Number of subjects: 63
Study 19064125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet Type I (WT group)
Number of subjects: 203
Study 19064125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet Type II (WT group)
Number of subjects: 203
Study 19064125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet Type I (mutant group)
Number of subjects: 203
Study 19064125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet Type II (mutant group)
Number of subjects: 203
Study 17855735 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural mepivacaine (0.15 ml kg(‐1) bolus of 2% mepivacaine, followed by 0.1 ml kg(‐1) h(‐1))
Number of subjects: 80
Study 17855735 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.04 mg kg(‐1) at 25% recovery of the first twitch of TOF)
Number of subjects: 80
Study 17855735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epidural mepivacaine)
Number of subjects: 80
Study 15196516 — intervention group
Group type: EXPERIMENTAL
Intervention: Handrail usage
Number of subjects: 30
Study 15196516 — intervention group
Group type: COMPARATOR
Intervention: Older adults
Number of subjects: 30
Study 15196516 — intervention group
Group type: COMPARATOR
Intervention: Walking velocity
Number of subjects: 30
Study 10753985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular urokinase treatment
Number of subjects: 20
Study 10753985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9816086 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐gamma at dose levels ranging from 0.01 to 0.90 mg/m2, administered as a 1‐h i.v. infusion three times per week for at least 8 weeks or until progressive disease.
Number of subjects: 98
Study 9816086 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐gamma
Number of subjects: 98
Study 1466326 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training at home for 8 weeks
Number of subjects: 25
Study 6547461 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenges
Number of subjects: 40
Study 6547461 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick skin tests (STs)
Number of subjects: 40
Study 6547461 — intervention group
Group type: EXPERIMENTAL
Intervention: RAST
Number of subjects: 40
Study 6547461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of STs and RASTs
Number of subjects: 40
Study 6547461 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin testing
Number of subjects: 40
Study 30611598 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive oral management protocol including spacers, pilocarpine hydrochloride, and topical dexamethasone ointment for oral mucositis
Number of subjects: 124
Study 30611598 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only oral care
Number of subjects: 124
Study 30428863 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with supervised foot-ankle exercises (twice a week for 12 weeks) and remotely supervised exercises for a year
Number of subjects: 77
Study 30428863 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 77
Study 26525162 — intervention group
Group type: EXPERIMENTAL
Intervention: IMR(s)
Number of subjects: 48
Study 26525162 — intervention group
Group type: EXPERIMENTAL
Intervention: IMR(c)
Number of subjects: 48
Study 22525130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nile Red stain
Number of subjects: 8
Study 22525130 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil Red O stain
Number of subjects: 8
Study 22525130 — intervention group
Group type: COMPARATOR
Intervention: Negative control lenses
Number of subjects: 8
Study 22525130 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-worn lotrafilcon A lenses
Number of subjects: 8
Study 20935397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast (10 mg/day)
Number of subjects: 50
Study 20935397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxophylline (400 mg/day)
Number of subjects: 50
Study 20935397 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 mcg)
Number of subjects: 50
Study 20935397 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 50
Study 17886090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-bicarbonated mineral water 1
Number of subjects: 18
Study 17886090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-bicarbonated mineral water 2
Number of subjects: 18
Study 17886090 — intervention group
Group type: COMPARATOR
Intervention: Low-mineral water
Number of subjects: 18
Study 16288079 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 12525444 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG‐IUS)
Number of subjects: 48
Study 12525444 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated tissue)
Number of subjects: 48
Study 10914614 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones
Number of subjects: 0
Study 8985525 — intervention group
Group type: EXPERIMENTAL
Intervention: Henna application
Number of subjects: 15
Study 8985525 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-henna-induced haemolysis)
Number of subjects: 15
Study 1531285 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet (40 mg/kg every 8 or 12 hours)
Number of subjects: 0
Study 1531285 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir maintenance following foscarnet induction therapy
Number of subjects: 0
Study 4061980 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline delivered by tube spacer
Number of subjects: 34
Study 4061980 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline delivered by conventional inhaler
Number of subjects: 34
Study 4061980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31423712 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity care (up-titration of oral HF medications including beta-blockers, ACE inhibitors or ARBs, and MRAs)
Number of subjects: 900
Study 31423712 — intervention group
Group type: COMPARATOR
Intervention: Usual care (managed according to usual clinical practice)
Number of subjects: 900